CompletedPhase 2NCT00093769

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Studying Indolent B-cell non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Jonsson Comprehensive Cancer Center
Principal Investigator
Sven De Vos, MD
Jonsson Comprehensive Cancer Center
Intervention
bortezomib + rituximab(drug)
Enrollment
15 enrolled
Eligibility
18 years · All sexes
Timeline
2004

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00093769 on ClinicalTrials.gov

Other trials for Indolent B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Indolent B-cell non-Hodgkin lymphoma →

← Back to all trials